Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia

Abstract Despite recent relevant therapeutic progresses, chronic lymphocytic leukemia (CLL) remains an incurable disease. Selinexor, an oral inhibitor of the nuclear export protein XPO1, is active as single agent in different hematologic malignancies, including CLL. The purpose of this study was to...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Candida Vitale, Valentina Griggio, Maria Todaro, Chiara Riganti, Rebecca Jones, Elia Boccellato, Francesca Perutelli, Francesca Arruga, Tiziana Vaisitti, Dimitar G. Efremov, Silvia Deaglio, Yosef Landesman, Benedetto Bruno, Marta Coscia
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Nature Portfolio 2023-10-01
Schriftenreihe:	Scientific Reports
Online-Zugang:	https://doi.org/10.1038/s41598-023-44039-0
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!